<DOC>
	<DOC>NCT02592057</DOC>
	<brief_summary>This study will evaluate the safety and efficacy of sofosbuvir (SOF)-based regimens administered as per the approved prescribing information in adults with chronic hepatitis C virus (HCV) infection treated in routine clinical practice in India.</brief_summary>
	<brief_title>Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>HCVinfected patients living in India Treatment with a SOFbased regimen as determined by the patient's treating physician per the approved prescribing information. Patients who provide written and signed informed consent prior to initiation of treatment where required. Concurrent participation in an HCV clinical trial (except trials not testing investigational medicinal products) Patients presenting a risk of not being able to be followed (eg, patients planning to move or leave the country in a foreseeable future)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>